Lercanidipine suffers another setback
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest says further development of the calcium channel blocker lercanidipine would require another extended-release formulation, after the current modified-release version failed to meet dose-response criteria in a Phase II study conducted in response to FDA's August 2002 "approvable" letter. Preliminary results of the eight-week, 60-patient efficacy study indicate lercanidipine was "well tolerated" and had a "clinically relevant reduction in blood pressure." Forest says the positive findings warrant further investigation. A new formulation would mean development "would accordingly be somewhat delayed," the company says. Lercanidipine is already three years behind the original launch projection…
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.